
Ryan Urak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/138484/publications.pdf Version: 2024-02-01



RVAN HDAK

#	Article	IF	CITATIONS
1	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunology Research, 2019, 7, 759-772.	3.4	235
2	Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Molecular Therapy, 2015, 23, 757-768.	8.2	169
3	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 2018, 24, 106-119.	7.0	136
4	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncolmmunology, 2018, 7, e1380764.	4.6	111
5	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. , 2017, 5, 26.		72
6	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research, 2015, 21, 2993-3002.	7.0	52
7	Comparison of naÃ ⁻ ve and central memory derived CD8 ⁺ effector cell engraftment fitness and function following adoptive transfer. Oncolmmunology, 2016, 5, e1072671.	4.6	25
8	Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator. Molecular Therapy, 2019, 27, 1737-1748.	8.2	25
9	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88.	3.4	24
10	Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy, 2017, 19, 861-866.	0.7	20
11	Improved Cas9 activity by specific modifications of the tracrRNA. Scientific Reports, 2019, 9, 16104.	3.3	19
12	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Research, 2018, 46, 7108-7123.	14.5	16
13	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461.		9
14	Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients. Oncolmmunology, 2022, 11, 2040772.	4.6	8
15	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR TÂcells with CMV vaccine. Molecular Therapy - Methods and Clinical Development, 2022, 25, 344-359.	4.1	6
16	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma. Blood, 2016, 128, 812-812.	1.4	4
17	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood, 2015, 126, 930-930.	1.4	2
18	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. Blood, 2014, 124, 1114-1114.	1.4	1

Ryan Urak

#	Article	IF	CITATIONS
19	Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor. Blood, 2021, 138, 1715-1715.	1.4	1
20	Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity. Blood, 2021, 138, 2796-2796.	1.4	1
21	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. Blood, 2015, 126, 3086-3086.	1.4	0
22	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161.	1.4	0